Pharmaceuticals
Egypt Diabetes Therapeutics Market Analysis
Egypt's diabetes therapeutics market is expected to witness growth from $403 Mn in 2022 to $942 Mn in 2030 with a CAGR of 11.2% for the forecasted year 2022-30. The higher prevalence rates of diabetes and the increased funding for the healthcare infrastructure in Egypt are responsible for the growth of the market. The Egypt diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel. Sovalue, Vortex Pharma, and AstraZeneca are the major players in the Egypt diabetes therapeutics market.
Buy Now
Egypt Diabetes Therapeutics Market Executive Analysis
Egypt's diabetes therapeutics market is at around $403 Mn in 2022 and is projected to reach $942 Mn in 2030, exhibiting a CAGR of 11.2% during the forecast period. A favorable climate for investment in Egyptian healthcare is being established through evolving laws, a growing population, and consumer demand for universal access to high-quality care. To modernize the dated national health insurance system, Universal Health Insurance Law No. 2 was implemented in 2018. The International Finance Corporation (IFC), the World Bank's private sector development arm, collaborates with the Egyptian government and private businesses on other projects to invest in the growth of Egypt's healthcare industry. With intentions to add another $400 Mn in the following two years, IFC has already invested $400 Mn in Egypt's healthcare industry. Most expenditures have been made in healthcare facilities like hospitals, clinics, and diagnostic centers.
DM is a problem and a rapidly growing issue in Egypt. The number of adult diabetic patients in Egypt was 8,850,400 in early 2020, with a prevalence of 15.2%, according to the International Diabetes Federation (IDF), placing Egypt tenth globally in terms of DM prevalence. IDF predicts that by 2045, there will be 108 Mn more diabetic patients in the MENA area than there are today.
The use of insulin is linked to a higher chance of hypoglycemia and weight gain, which reduces its efficacy and leads to inadequate glycemic control. In addition, the majority of patients are hesitant to begin insulin therapy due to pain and injection frequency fears, which frequently leads to skipping insulin injections. Combining incretin therapy with insulin can help overcome these limitations because incretins improve glycemic control by increasing the sensitivity of alpha and beta-cells to glucose without increasing the risk of hypoglycemia or weight gain typically linked with insulin. Vildagliptin, a specific DPP-4 inhibitor, increases glucose-dependent insulin secretion from pancreatic beta-cells without increasing the risk of hypoglycemia or weight gain. Vildagliptin's efficacy and safety as an addition to insulin have been proven in a number of randomized clinical trials (RCTs), but there is barely any information available in Egypt regarding the drug's efficacy and safety in practical contexts.
Market Dynamics
Market Growth Drivers
Diabetic prevalence is among the highest in the world in Egypt. The demand for diabetes therapeutics is being driven by this rising incidence. Egypt's government is making significant investments in the healthcare industry. Access to healthcare services and medications, including diabetes therapeutics, has improved because of this. The acceptance of contemporary lifestyles, such as sedentary employment and a diet heavy in processed foods, is a factor in Egypt's rising diabetes rate. The need for diabetes treatments is being driven by this. Treatments for diabetes have made major strides in recent years. These developments have produced novel, more potent diabetes medicines, which are fuelling the Egypt diabetes therapeutics market's expansion.
Market Restraints
While the Egyptian government is investing in the healthcare industry, there are still challenges in terms of healthcare infrastructure. This may restrict access to medical treatments and medicines, including those for treating diabetes. Diabetes medications can be expensive, which makes it challenging for some patients to pay for treatments. This poses a major obstacle to patients with low incomes getting access to diabetes treatments. The Egyptian government is making investments in the healthcare industry, but there may not be enough money for research and development on diabetes. This may restrict access to newer, more potent diabetes treatments hence limiting the expansion of the Egypt diabetes therapeutics market.
Competitive Landscape
Key Players
- Salix Pharma (EGY)
- Sehha Pharmacies (EGY)
- Suecal pharmaceutical (EGY)
- Sovalue (EGY)
- Vortex pharma (EGY)
- Astrazeneca
- Boehringer Ingelheim
- Eli Lilly
- Glaxosmithkline
- Novartis
- Novo Nordisk
Healthcare Policies and Regulatory Landscape
The Egyptian Drug Authority (EDA), which is governed by Egypt's Ministry of Health (MOH), is the country's pharmaceutical regulatory authority. The primary duties of the Central Administration for Pharmaceutical Affairs (CAPA) include inspecting pharmacies and manufacturing sites as well as registering and pricing medicines. The CAPA has four registration-related departments: Importation and Exportation, Inspection and Control, and Licensing and Pharmacist Services. The Egyptian Pharmacovigilance Centre, or "EPVC," is a division of the CAPA that keeps track of how medicines and medical equipment are used after they have been registered. The National Organization for Drug Control and Research (NODCR) is in charge of monitoring the purity of pharmaceuticals, drugs, medical plants, cosmetics, raw materials, insecticides, and naturally derived goods. For the purpose of testing all registered pharmaceutical products that will be sold in Egypt, the organization employs numerous labs. The National Organization for Research & Control of Biologicals (NORCB) is in charge of the licensing and marketing permission procedures.
1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country
2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)
3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints
4. Competitive Landscape
4.1 Major Market Share
4.2 Key Company Profile (Check all Companies in the Summary Section)
4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)
5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment
6. Methodology and Scope
Diabetes Therapeutics Segmentation
By Type (Revenue, USD Billion):
- Diabetes 1
- Diabetes 2
By Application (Revenue, USD Billion):
- Preventive
- Prediabetes
- Nutrition
- Obesity
- Lifestyle Management
- Treatment/Care
- Diabetes
- Smoking Cessation
- Musculoskeletal Disorders
- Central Nervous System Disorders
- Cardiovascular Disease
- Medication Adherence
- Chronic Respiratory Disorders
- Gastrointestinal Disorders
- Rehabilitation
- Substance Use Disorders & Addiction Management
By Drug (Revenue, USD Billion):
- Oral Anti-diabetic Drugs
- Insulin
- Non-insulin Injectable Drug
- Combination Drug
By Route of Administration (Revenue, USD Billion):
- Oral
- Subcutaneous
- Intravenous
By Distribution Channel (Revenue, USD Billion):
- Online Pharmacies
- Hospital Pharmacies
- Retail Pharmacies
Methodology for Database Creation
Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.
Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.
How Do We Get It?
Our database is created and maintained through a combination of secondary and primary research methodologies.
1. Secondary Research
With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:
- Analyzing historical proprietary data collected from multiple projects.
- Regularly updating our existing data sets with new findings and trends.
- Ensuring data consistency and accuracy through rigorous validation processes.
With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:
- Searching through academic conferences, published research, citations, and social media platforms
- Collecting and compiling diverse data to build a comprehensive and detailed database
- Continuously updating our database with new information to ensure its relevance and accuracy
2. Primary Research
To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:
- Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
- Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
- Continuously refreshing our database to ensure that the information remains current and reliable.
- Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.
Combining Secondary and Primary Research
By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:
- Merging historical data from secondary research with real-time data from primary research.
- Conducting thorough data validation and cleansing to remove inconsistencies and errors.
- Organizing data into a structured format that is easily accessible and usable for various applications.
- Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.
Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.
To request a free sample copy of this report, please complete the form below.
We value your inquiry and offer free customization with every report to fulfil your exact research needs.
Sovalue, Vortex pharma, and Astrazeneca are the major players in the Egypt diabetes therapeutics market.
The Egypt diabetes therapeutics market is expected to grow from $403 Mn in 2022 to $942 Mn in 2030 with a CAGR of 11.2% for the forecasted year 2022-2030.
The Egypt diabetes therapeutics market is segmented by type, application, drug, route of administration, and distribution channel.
Related reports (by category)
Pharmaceuticals
Singapore Antiepileptics Drugs Market Analysis
Pharmaceuticals
Singapore Pressure Sensor Market Analysis
Pharmaceuticals
UAE Kidney Cancer Drugs Market Analysis
Related reports (by geography)
Pharmaceuticals
Egypt Diabetes Management Market Analysis
Pharmaceuticals
Egypt pH Meters Market Analysis
OTC & Nutraceuticals
Egypt Over The Counter (OTC) Pharmaceuticals Market Analysis
Pharmaceuticals
